首页> 外文期刊>Clinical infectious diseases >Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.
【24h】

Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream.

机译:局部和全身抗菌疗法治疗轻度感染的糖尿病足溃疡:皮克西加南霜的随机,对照,双盲,多中心试验。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: Topical antimicrobial therapy of infected diabetic foot ulcers can focus on the wound and avoid the adverse effects of systemic anti-infective agents. We compared the efficacy of outpatient treatment using an investigational topical antimicrobial peptide, pexiganan acetate cream, with the efficacy of systemic therapy using an oral fluoroquinolone antibiotic, ofloxacin, for mildly infected diabetic foot ulcers. METHODS: In 2 consecutive, double-blind, controlled trials (study 303 and study 304), we randomized diabetic patients with a mildly infected diabetic foot ulcer to receive the active topical agent or active oral antibiotic, plus a respective inactive placebo. The primary outcome of interest was clinical cure or improvement of the infection. Secondary outcomes included eradication of wound pathogens and wound healing, which was documented by a semiquantitative scoring system. RESULTS: Overall, 835 patients were randomized; those in each treatment arm were similar with regard to demographic and clinical characteristics. Although study 303 failed to demonstrate equivalence, study 304 and the combined data for the 2 trials demonstrated equivalent results (within the 95% confidence interval) for topical pexiganan and oral ofloxacin in clinical improvement rates (85%-90%), overall microbiological eradication rates (42%-47%), and wound healing rates. The incidence of worsening cellulitis (2%-4%) and amputation (2%-3%) did not differ significantly between treatment arms. Bacterial resistance to ofloxacin emerged in some patients who received ofloxacin, but no significant resistance to pexiganan emerged among patients who received pexiganan. CONCLUSIONS: Topical pexiganan might be an effective alternative to oral antibiotic therapy in treating diabetic patients with a mildly infected foot ulcer, and might reduce the risk of selecting antimicrobial-resistant bacteria.
机译:背景:感染的糖尿病足溃疡的局部抗菌治疗可以集中在伤口上,避免全身性抗感染药的不良反应。我们比较了使用研究性局部抗菌肽,醋酸佩克西南乳膏的门诊治疗与使用口服氟喹诺酮抗生素氧氟沙星的全身治疗对轻度感染的糖尿病足溃疡的疗效。方法:在2个连续的双盲,对照试验(研究303和研究304)中,我们将患有轻度感染的糖尿病足溃疡的糖尿病患者随机分配接受活性局部用药或活性口服抗生素,以及各自无效的安慰剂。感兴趣的主要结果是临床治愈或感染的改善。次要结果包括根除伤口病原体和伤口愈合,这通过半定量评分系统进行了记录。结果:总共有835例患者被随机分组​​。各治疗组在人口统计学和临床​​特征方面相似。尽管研究303未能证明其等效性,但研究304和两项试验的合并数据表明,局部培昔加南和口服氧氟沙星的临床改善率(85%-90%),总体微生物根除率具有相同的结果(在95%置信区间内)率(42%-47%)和伤口愈合率。治疗组之间恶化的蜂窝织炎(2%-4%)和截肢(2%-3%)的发生率无显着差异。在接受氧氟沙星的一些患者中出现了对氧氟沙星的细菌耐药性,但在接受哌克昔南的患者中未出现对培昔加南的显着耐药性。结论:局部佩奇高聚糖可能是治疗轻度感染足溃疡的糖尿病患者的口服抗生素治疗的有效替代方法,并可能降低选择抗微生物细菌的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号